Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 2/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616346 | 0.86 | MET (0.48) | ESR1ESR2METKITFGFR1 | |
| SCHEMBL616469 | 0.82 | ESR1 (0.43) | ESR1ESR2METKITFGFR1 | |
| SCHEMBL14374109 | 0.82 | ESR1 (0.36) | ESR1ESR2METKITFGFR1 | |
| Idronoxil SCHEMBL149612 | 0.72 | ESR2 (0.49) | ESR1ESR2TYRRARARARG | |
| Idronoxil SCHEMBL29353213 | 0.72 | ESR2 (0.49) | ESR1ESR2TYRRARARARG | |
| SCHEMBL677785 | 0.71 | ESR2 (0.42) | ESR1ESR2TYRRARARARG | |
| SCHEMBL615450 | 0.71 | TYR (0.43) | ESR1ESR2TYRRARARARG | |
| SCHEMBL616661 | 0.70 | ESR1 (0.43) | ESR1ESR2METKITFGFR1 | |
| SCHEMBL26549421 | 0.68 | NISCH (0.48) | ESR1ESR2RARARARGALOX5 | |
| SCHEMBL31069510 | 0.66 | GSK3B (0.40) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367659-B2 | Oxazinyl isoflavonoid compounds, medicaments and use | MARSHALL EDWARDS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2125831-B1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RES PTY LTD (AU) | 2011-12-28 | — | — | EP | disclosed |
| EP-2334296-A1 | IMMUNOMODULATING ACTIVITIES | Novogen Research Pty. Ltd. (AU) | 2011-06-22 | — | — | EP | disclosed |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2011-02-24 | — | — | US | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-2125831-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | Novogen Research Pty. Ltd. (AU) | 2009-12-02 | — | — | EP | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| WO-2008106715-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | ESR1 138/4885ESR2 43/4885MET 1596/4885 |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | TNNI3, NFE2L2, OAT | ESR1 138/4885ESR2 85/4885MET 3794/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | ESR1 291/4885ESR2 57/4885MET 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.